Noxopharm Ltd has released a press release.
HERACLES clinical trial Update 2
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- US company demonstrates strong Sofra potential
- June 2025 Quarterly Activities Report and Appendix 4C
- HERACLES clinical trial - Update 1
- First SOF-SKN dose in HERACLES clinical trial
- Promising Sofra results from overseas company
Later from Noxopharm
- HERACLES clinical trial Update 3
- Appendix 4E Preliminary Final Report
- HERACLES clinical trial Update 4
- Extension of Convertible Notes and Funding
- First US patent for Sofra technology platform
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm